Penserra Capital Management LLC Corbus Pharmaceuticals Holdings, Inc. Transaction History

Penserra Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$0.32 - $0.67 $171,915 - $359,948	-537,236 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$0.6 - $1.11 $61,417 - $113,621	102,362 Added 23.54%	537,236 $330,000
Q3 2021 Nov 15, 2021	BUY	$1.01 - $1.82 $70,609 - $127,236	69,910 Added 19.16%	434,874 $443,000
Q2 2021 Aug 12, 2021	BUY	$1.39 - $2.21 $340,516 - $541,396	244,976 Added 204.17%	364,964 $667,000
Q1 2021 May 13, 2021	BUY	$1.27 - $3.42 $19,786 - $53,283	15,580 Added 14.92%	119,988 $236,000
Q4 2020 Feb 12, 2021	BUY	$0.94 - $1.89 $9,212 - $18,522	9,800 Added 10.36%	104,408 $130,000
Q3 2020 Nov 13, 2020	SELL	$1.5 - $9.38 $35,076 - $219,341	-23,384 Reduced 19.82%	94,608 $170,000
Q2 2020 Aug 14, 2020	SELL	$4.79 - $8.39 $146,334 - $256,314	-30,550 Reduced 20.57%	117,992 $989,000
Q1 2020 May 14, 2020	BUY	$3.44 - $7.21 $510,984 - $1.07 Million	148,542 New	148,542 $978,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $853M
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.